Overview

* Immunovant ( IMVT ) Q2 net loss misses analyst expectations

* Company advances IMVT-1402 trials across multiple indications, contributing to increased R&D expenses

* Immunovant ( IMVT ) maintains strong cash position, supporting trials through GD readout in 2027

Outlook

* Company plans to report IMVT-1402 trial results in 2026 and 2027

* Current cash supports operations through GD readout in 2027

Result Drivers

* INCREASED R&D EXPENSES - Higher R&D expenses due to clinical trials of IMVT-1402, including contract manufacturing costs and personnel-related expenses

* Research and development (R&D) expenses were $114.2 million for the three months ended September 30, 2025, compared to $97.3 million for the three months ended September 30, 2024

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Net Miss -$126.50 -$123.42

Income mln mln (12

Analysts

)

Q2 Basic -$0.73

EPS

Q2 $131.76

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Immunovant Inc ( IMVT ) is $44.00, about 46.9% above its November 7 closing price of $23.35

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)